Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.76 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.76 |
| ▸ | FAAH | O00519 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | IDE | P14735 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12382069 | 0.94 | S1PR1 (0.77) | S1PR1S1PR3FAAHMEN1MAPT | |
| SCHEMBL12315656 | 0.91 | S1PR1 (0.68) | S1PR1S1PR3FAAHMEN1MAPT | |
| SCHEMBL12315641 | 0.86 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL19481508 | 0.85 | FAAH (1.00) | S1PR1S1PR3FAAHMEN1MAPT | |
| SCHEMBL17309376 | 0.85 | FAAH (1.00) | S1PR1S1PR3FAAHMEN1MAPT | |
| SCHEMBL12382068 | 0.84 | S1PR1 (0.75) | S1PR1S1PR3MEN1KMT2AALDH1A1 | |
| SCHEMBL12315629 | 0.81 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL31310561 | 0.79 | FAAH (0.83) | S1PR1S1PR3FAAHMEN1MAPT | |
| SCHEMBL12315643 | 0.78 | S1PR1 (0.75) | S1PR1S1PR3MEN1KMT2AALDH1A1 | |
| SCHEMBL16130327 | 0.78 | S1PR1 (0.66) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912340-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912340-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-16 | — | — | US | disclosed |
| EP-2489662-B1 | Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-8263780-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263780-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2489662-A1 | New process for the preparation of 2-imino-thiazolidin-4-one derivatives | Actelion Pharmaceuticals Ltd. (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | VANDA PHARMACEUTICALS INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | VANDA PHARMACEUTICALS INC. | 2011-08-18 | — | — | US | disclosed |
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-16 | — | — | US | disclosed |
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-16 | — | — | US | disclosed |
| WO-2008062376-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | IL4, IL15, IL2 | S1PR1 3394/4885S1PR3 3399/4885FAAH 4751/4885 |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | IL4, IL2, IL15 | S1PR1 3355/4885S1PR3 3539/4885FAAH 4677/4885 |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | IL4, IL15, IL2 | S1PR1 3394/4885S1PR3 3399/4885FAAH 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.